Coordinated regulation of the immunoproteasome subunits by PML/RAR and PU.1 in acute promyelocytic leukemia

Oncogene

Volumn 33, Issue 21, 2014, Pages 2700-2708

  Yang, X W ^a   Wang, P ^a   Liu, J Q ^a   Zhang, H ^a   Xi, W D ^a   Jia, X H ^a   Wang, K K ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

APL; ATRA; Immunoproteasome subunits; PML RARa; PU.1

Indexed keywords

ARSENIC TRIOXIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOPROTEASOME SUBUNIT; MESSENGER RNA; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PSMB10 PROTEIN; PSMB8 PROTEIN; PSMB9 PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE REPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LEUKEMOGENESIS; LUCIFERASE ASSAY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; TRANSACTIVATION; U937 CELL LINE;

ANTIGEN PRESENTATION; ARSENICALS; CYSTEINE ENDOPEPTIDASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NUCLEAR PROTEINS; OXIDES; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS; RECEPTORS, RETINOIC ACID; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; TRETINOIN; TUMOR ESCAPE; TUMOR SUPPRESSOR PROTEINS;

EID: 84901497539     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.224     Document Type: Article

References (52)

1. Rousselot P Hardas B Patel A Guidez F Gaken J Castaigne S et al. The PML-RAR alpha gene product of the t (15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene 1994; 9: 545-551.
2. Grignani F Ferrucci PF Testa U Ta lamo G Fagioli M Alcalay M et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431. (Pubitemid 23244608)
3. Grignani F De Matteis S Nervi C Tomassoni L Gelmetti V Cioce M et al Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia Nature 1998 391 815-818. (Pubitemid 28099683)
4. Lin RJ Sternsdorf T Tini M Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001; 20: 7204-7215. (Pubitemid 33105009)
5. Hu J Liu YF Wu CF Xu F Shen ZX Zhu YM et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 3342-3347.
6. Wang ZY Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-2515.
7. Zheng PZ Wang KK Zhang QY Huang QH Du YZ Zhang QH et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 2005; 102: 7653-7658.
8. Doucas V Brockes JP Yaniv M de The H Dejean A. The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic aciddependent activator of transcription factor AP-1. Proc Natl Acad Sci USA 1993; 90: 9345-9349. (Pubitemid 23315780)
9. Wang K Wang P Shi J Zhu X He M Jia X et al. PML/RARalpha targets p romoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 2010; 17: 186-197.
10. Tsuzuki S Towatari M Saito H Enver T. Potentiation of GATA-2 a ctivity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein. Mol Cell Biol 2000; 20: 6276-6286. (Pubitemid 30650214)
11. Jansen JH Mahfoudi A Rambaud S Lavau C Wahli W Dejean A. Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci USA 1995; 92: 7401-7405.
12. Hoemme C Peerzada A Behre G Wang Y McClelland M Nieselt K et al. Chromatin modifications induced by PML-RARalpha repress critical tar gets in leukemogenesis as analyzed by ChIP-Chip. Blood 2008; 111: 2887-2895.
13. Aptsiauri N Cabrera T Garcia-Lora A Lopez-Nevot MA Ruiz-Cabello F Garrido F. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256: 139-189. (Pubitemid 46109029)
14. Goldberg AL Gaczynska M Grant E Michalek M Rock KL. Functions of the proteasome in antigen presentation. Cold Spring Harb Symp Quant Biol 1995; 60: 479-490. (Pubitemid 26202058)
15. Rock KL Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999; 17: 739-779. (Pubitemid 29241139)
16. Seliger B Maeurer MJ Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-464.
17. Zheng P Guo Y Niu Q Levy DE Dyck JA Lu S et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998; 396: 373-376. (Pubitemid 28557398)
18. Promsuwicha O Auewarakul CU. Positive and nega tive predictive values of HLADR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations. Asian Pac J Allergy Immunol 2009; 27: 209-216.
19. Vertuani S De Geer A Levitsky V Kogner P Kiessling R Levitskaya J. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymph ocytes. Cancer Res 2003; 63: 8006-8013. (Pubitemid 37466739)
20. Padua RA Larghero J Robin M le Pogam C Schlageter MH Muszlak S et al. PMLRARA-targeted DNA vaccine induces protective immunity in a mou se model of leukemia. Nat Med 2003; 9: 1413-1417. (Pubitemid 37466192)
21. Robin M Andreu-Gallien J Schlageter MH Bengoufa D Guillemot I Pokorna K et al. Frequent antibody production against RARalpha in both APL mice and patients. Blood 2006; 108: 1972-1974 . (Pubitemid 44395008)
22. Zhu X Zhang H Qian M Zhao X Yang W Wang P et al. The significance of low PU.1 expression in patients with acute promyelocytic leukemia. J Hematol Oncol 2012; 5: 22.
23. Wouters BJ Lowenberg B Erpelinck-Verschueren CA van Putten WL Valk PJ Delwel R. Double CEBPA mutations but not single CEBPA mutations define a subgroup of acute myeloid leukemia with a distinctive gene exp ression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088-3091.
24. Ross ME Mahfouz R Onciu M Liu HC Zhou X Song G et al. Gene expression profiling of pediatric acute myelogenous leukemia Blood 2004 104 3679-3687. (Pubitemid 39564445)
25. Tomasson MH Xiang Z Walgren R Zhao Y Kasai Y Miner T et al. Somatic mutations and germline sequence var iants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111: 4797-4808.
26. Hallermalm K Seki K Wei C Castelli C Rivoltini L Kiessling R et al. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway resulting in increased stability of class I complexes at the cell surface. Blood 2001; 98: 1108-1115.
27. Olive V Wagner N Chan S Kastner P Vannetti C Cuzin F et al. PU.1 (Sfpi1) a pleiotropic regulator expressed from the first embryonic stages with a crucial function in germinal progenitors. Develo pment 2007; 134: 3815-3825. (Pubitemid 350187341)
28. Singh H. PU.1 a shared transcriptional regulator of innate and adaptive immune cell fates. J Immunol 2008; 181: 1595-1596.
29. Carotta S Wu L Nutt SL. Surprising new roles for PU.1 in the adaptive immune response. Immunol Rev 2010; 238: 63-75.
30. Spain LM Guerriero A Kunjibettu S Scott EW. T cell development in PU.1-deficient mice. J Immunol 1999; 163: 2681-2687. (Pubitemid 29399193)
31. Lloberas J Soler C Celada A. The key role of PU.1/SPI-1 in B cells myeloid cells and macrophages. Immunol Today 1999; 20: 184-189. (Pubitemid 29172282)
32. Carotta S Dakic A D 'Amico A Pang SH Greig KT Nutt SL et al. The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor ex pression in a dose-dependent manner. Immunity 2010; 32: 628-641.
33. Kanada S Nishiyama C Nakano N Suzuki R Maeda K Hara M et al. Critical role of transcription factor PU.1 in th e expression of CD80 and CD86 on dendritic cells. Blood 2011; 117: 2211-2222.
34. Smith-Garvin JE Koretzky GA Jordan MS. T cell activation. Annu Rev Immunol 2009; 27: 591-619.
35. Lecchi M Lovisone E Genetta C Peruccio D Resegotti L Richiardi P. Gamma-IFN induces a differential expression of HLA-DR DQ and DP antigens on peripheral blood myeloid leukemic blasts at various stages of differentiation. Leuk Res 1989; 13: 221-226. (Pubitemid 19107933)
36. Jinnai I. In vitro growth response to G-CSF and GM-CSF by bone marrow cells of patients with acute myeloid leukemia. Leuk Res 1990; 14: 227-240. (Pubitemid 20120462)
37. Larsen F Solheim J Kristensen T Kolsto AB Prydz H. A tight cluster of five unrelated human genes on chromosome 16q22.1. Hum Mol Genet 1993; 2: 1589-1595. (Pubitemid 23358675)
38. Lowe nberg B Griffin JD Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematol Am Soc Hematol Educ Program 2003; 82-101.
39. Zhang Y Zhang Z Li J Li L Han X Han L et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 2013; 119: 115-125.
40. Shen ZX Shi ZZ Fang J Gu BW Li JM Zhu YM et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335. (Pubitemid 38481160)
41. Zheng X Seshire A Ruster B Bug G Beissert T Puccetti E et al. Arsenic but not alltrans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalphapositive leukemic stem cell s. Haematologica 2007; 92: 323-331. (Pubitemid 350143541)
42. Huang ME Ye YC Chen SR Chai JR Lu JX Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
43. Idres N Benoit G Flexor MA Lanotte M Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. Cancer Res 2001; 61: 700-705. (Pubitemid 32128635)
44. Maeda Y Horiuchi F Miyatake J Sono H Tatsumi Y Urase F et al. Inhibition of growth and induction of apoptosis by all-trans retinoic acid in lymp hoid cell lines transfected with the PML/RAR alpha fusion gene. Br J Haematol 1996; 93: 973-976. (Pubitemid 26199342)
45. Collins SJ. Retinoic acid receptors hematopoiesis and leukemogenesis Curr Opin Hematol 2008; 15 346-351.
46. Schlenk RF Frohling S Hartmann F Fischer JT Glasmacher A del Valle F et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18: 1798-1803. (Pubitemid 39534320)
47. Hu ZB Minden MD McCulloch EA. Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. Blood 1998; 92: 1768-1775. (Pubitemid 28406883)
48. Carter BZ Milella M Altieri DC Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001; 97: 2784-2790.
49. Meijerink J Mandigers C van de Locht L Tonnissen E Goodsaid F Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001; 3: 55-61. (Pubitemid 32440243)
50. Nigten J Breems-de Ridder MC Erpelinck-Verschueren CA Nikoloski G van der Reijden BA van Wageningen S et al. ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells. Leukemia 2005; 19: 799-805. (Pubitemid 40663100)
51. Zou D Yang X Tan Y Wang P Zhu X Yang W et al. Regulation of the hemat opoietic cell kinase (HCK) by PML/RARalpha and PU.1 in acute promyelocytic leukemia. Leuk Res 2012; 36: 219-223.
52. Carroll JS Liu XS Brodsky AS Li W Meyer CA Szary AJ et al. Ch romosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 122: 33-43. (Pubitemid 40977938)